1. Inoperable stage IIIb/IV histologically/cytologically confirmed lung adenocarcinoma

          2. EGFR mutation and EML4-ALK translocation negative

          3. Patients with evaluable but unmeasurable disease can be included in the phase I study,
             but disease must be measurable (CT scan must be within 28 days of randomisation) to be
             included in the phase II study

          4. ECOG performance status of 0 or 1

          5. Life expectancy of at least 12 weeks

          6. Age at least 18 years

          7. Adequate haematological status:

               1. Haemoglobin ≥100g/L

               2. Neutrophil count ≥1.5 x 109/L

               3. Platelets ≥100 x 109 /L

          8. Adequate organ function:

               1. Bilirubin ≤1.5 x ULN

               2. ALT or AST ≤3 x ULN (≤5 x ULN is acceptable with liver metastases)

               3. Creatinine clearance ≥ 60 ml/min (C&G or EDTA)

          9. Negative pregnancy test for female patients of child bearing potential.

         10. Male subjects and women of child bearing potential must agree to use an acceptable
             method of birth control for the duration of the trial and for 12 months after the last
             trial treatment administration.

         11. Ability to understand and provide written informed consent

         12. Ability to comply with the requirements of the protocol

        Exclusion Criteria:

          1. Prior chemotherapy, hormonal therapy, radiotherapy (including palliative
             radiotherapy), immunotherapy or treatment with an investigational drug for advanced
             NSCLC.

          2. Any surgical procedure in the previous 6 weeks prior to registration/ randomisation

          3. Known respiratory failure with baseline resting SpO2 <88%

          4. Long term oxygen therapy

          5. Severe intercurrent infection

          6. Active or infected wounds

          7. Yellow fever vaccination within 30 days prior to trial registration/randomisation

          8. Subject has known sensitivity to any of the trial drugs to be administered during the
             trial.

          9. Any contraindication to the administration and use of cisplatin, pemetrexed, vitamin
             B12 or folic acid

         10. Prior malignancy other than NSCLC (except if the tumour was a non-melanoma skin tumour
             that has been completely excised or in situ cervix carcinoma), unless have been
             treated with curative intent with no evidence of disease for > 3 years

         11. Evidence of symptomatic brain metastases requiring treatment

         12. Myocardial infarction, or unstable or uncontrolled disease or condition related to or
             impacting cardiac function (e.g., unstable angina, congestive heart failure [New York
             Heart Association > class II]) within 1 year of enrolment

         13. Known inflammatory bowel disease

         14. Known hepatitis B or C infection, human immunodeficiency virus (HIV)-positive patients

         15. Pregnant women or those who are breast feeding

         16. Other medications, severe acute/chronic medical or psychiatric condition, or
             laboratory abnormality that may increase the risk associated with trial participation
             or trial drug administration, or may interfere with the interpretation of trial
             results, and in the judgment of the investigator would make the patient inappropriate
             for entry into this trial